Indivior Pharmaceuticals, Inc. INDV Income Statement
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| $1.24B+4.3% | $1.19B+8.8% | $1.09B+21.3% | ||
| $246M+6.5% | $231M+32.8% | $174M+15.2% | ||
| $994M+3.8% | $958M+4.2% | $919M+22.5% | ||
| 80.2%-0.4pp | 80.6%-3.5pp | 84.1%+0.8pp | ||
| $97M-9.3% | $107M-7.8% | $116M+56.8% | ||
| $635M+3.8% | $612M+8.3% | $565M+21.2% | ||
| —— | $920M-14.2% | $1.07B+29.6% | ||
| —— | $920M-14.2% | $1.07B+29.6% | ||
| $262M+589% | $38M+125% | -$152M-97.4% | ||
| 21.1%+17.9pp | 3.2%+17.1pp | -13.9%-5.4pp | ||
| $45M+7.1% | $42M+20.0% | $35M+29.6% | ||
| $22M-4.3% | $23M-46.5% | $43M+126% | ||
| —— | —— | —— | ||
| $239M+1,095% | $20M+114% | -$145M-68.6% | ||
| —— | $13M+168% | -$19M+55.8% | ||
| $209M+2,886% | $7M+106% | -$126M-200% | ||
| 16.9%+16.3pp | 0.6%+12.1pp | -11.5%-6.9pp | ||
| $1.64+3,180% | $0.05+105% | -$0.92-207% | ||
| $1.68+3,260% | $0.05+105% | -$0.92-207% | ||
| 508M-5.6% | 538M— | —— | ||
| 499M-6.7% | 535M— | —— | ||
| $97M-9.3% | $107M-7.8% | $116M+56.8% | ||
| $1.24B+4.3% | $1.19B+8.8% | $1.09B+21.3% | ||
| $262M+589% | $38M+125% | -$152M-97.4% | ||
| $272M+404% | $54M+139% | -$137M-125% | ||
| $272M+404% | $54M+139% | -$137M-125% | ||
| 21.9%+17.4pp | 4.5%+17.1pp | -12.5%-5.8pp | ||
| $262M+589% | $38M+125% | -$152M-97.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Indivior Pharmaceuticals, Inc. 's profit margins?
- Gross margin is 81.3% and operating margin is 25.8%, with a 19.4% net margin.
- Where does Indivior Pharmaceuticals, Inc. 's income statement data come from?
- Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.